RUNX1 and myeloproliferative neoplasm: Regarding the type of malignant neoplasms, 37 individuals were diagnosed with AML (61%), nine with MDS (15%), seven with MDS/AML (11%), four with lymphoblastic HM (i.e., B- and T-ALL, 7%), and four with other myeloid malignancies (i.e., myeloproliferative neoplasm, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, 7%) (Figure 1), which resembles the distribution of malignancy types in the RUNX1 database (RUNX1db) [35].